Research programme: eye surgery therapeutics - Schering-Plough

Drug Profile

Research programme: eye surgery therapeutics - Schering-Plough

Alternative Names: rAd-p21

Latest Information Update: 24 Aug 2009

Price : $50

At a glance

  • Originator Schering-Plough; University of Wisconsin-Madison
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Wounds

Most Recent Events

  • 24 Aug 2009 Discontinued - Preclinical for Wounds in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top